BRIEF—Astellas and KM Biologics to end distribution agreement

Japan’s Astellas Pharma and KM Biologics have announced the imminent expiration of an agreement whereby Astellas has been distributing the latter’s human vaccines and blood plasma products.

After the deal expires on July 31, 2019, KM Biologics will regain distribution rights in Japan.

KM Biologics has reached a deal with Japan Blood Products Organization to distribute its blood plasma products from August 2019.